Streng, Koen W. http://orcid.org/0000-0002-0484-5268
Hillege, Hans L.
ter Maaten, Jozine M.
van Veldhuisen, Dirk J.
Dickstein, Kenneth
Samani, Nilesh J.
Ng, Leong L.
Metra, Marco
Filippatos, Gerasimos S.
Ponikowski, Piotr
Zannad, Faiez
Anker, Stefan D.
van der Meer, Peter
Lang, Chim C.
Voors, Adriaan A.
Damman, Kevin
Funding for this research was provided by:
Hartstichting ([CVON2014-11 RECONNECT)
FP7 Ideas: European Research Council (FP7-242209-BIOSTAT-CHF)
Article History
Received: 22 August 2022
Accepted: 18 January 2023
First Online: 16 February 2023
Declarations
:
: The study complied with the Declaration of Helsinki, the local ethics committee has approved the research protocol, and all the patients signed informed consent.
: M.M. received the following personal fees of minimal amounts in the last 3 years: from Actelion, Amgen, Livanova, Servier and Vifor pharma as member of Executive or Data Monitoring Committees of sponsored clinical trials; from Astra-Zeneca, Abbott vascular, Bayer, Boheringer Ingelhelm and Edwards Therapeutics for participation to advisory boards and/or speeches at sponsored meetings. S.D.A. reports receiving fees from Abbott, Actimed, Bayer, Boehringer Ingelheim, Cardiac Dimension, Cordio, Impulse Dynamics, Novartis, Occlutech, Servier and Vifor Pharma and grant support from Abbott and Vifor Pharma. C.C.L. received consultancy fees and/or research grants from Amgen, Astra Zeneca, MSD, Novartis and Servier. A.A.V Amgen, Bayer, Boehringer Ingelheim, Merck/MSD, Novartis, Roche Diagnostics, Servier, Trevena and Vifor. All the other authors declare no conflict of interest.